We are live on ! Find out more
LIPO

Lipella Pharmaceuticals
LIPO

Delisted

LIPO was delisted on the 18th of June, 2025.

Back to rankings

6 hedge funds and large institutions have $104K invested in Lipella Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

200% more funds holding

Funds holding: 2 → 6 (+4)

132% more capital invested

Capital invested by funds: $44.7K → $104K (+$58.9K)

0.68% more ownership

Funds ownership: 0.25% → 0.93% (+0.68%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+4
Holders Change %
+200%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$90.6K
2
TSS
Two Sigma Securities
New York
+$32.1K
3
TRCT
Tower Research Capital (TRC)
New York
+$5.42K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$137
5
Wells Fargo
Wells Fargo
California
+$20

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$39.8K
2
UBS Group
UBS Group
Switzerland
-$1.86K

LIPO Hedge Fund Activity: Q1 2023 in Review

6 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q1 2023, worth a combined $104K — up 132% from $44.7K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new LIPO positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $90.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $39.8K sold.

  • 6 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q1 2023, up from 2 in Q4 2022.
  • Funds reported $104K of Lipella Pharmaceuticals stock for Q1 2023, up 132% quarter-over-quarter.
  • 5 funds opened new Lipella Pharmaceuticals positions in Q1 2023 and 1 closed out, a net change of +4 holders.
  • The largest Lipella Pharmaceuticals buyer in Q1 2023 was Vanguard Group, an estimated $90.6K added.
  • The largest Lipella Pharmaceuticals seller in Q1 2023 was Citadel Advisors, an estimated $39.8K sold.

Based on aggregated 13F filings for Q1 2023.